TherapeuticsMD - TXMD Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $125.00
  • Forecasted Upside: 1,137.62 %
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 2 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$10.10
▼ -0.1 (-0.98%)

This chart shows the closing price for TXMD by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New TherapeuticsMD Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for TXMD and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for TXMD

Analyst Price Target is $125.00
▲ +1,137.62% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for TherapeuticsMD in the last 3 months. The average price target is $125.00, with a high forecast of $125.00 and a low forecast of $125.00. The average price target represents a 1,137.62% upside from the last price of $10.10.

This chart shows the closing price for TXMD for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Hold

The current consensus among 2 polled investment analysts is to hold stock in TherapeuticsMD. This rating has held steady since April 2022, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 1 sell ratings
2/24/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 1 sell ratings
5/25/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
8/23/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
11/21/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
2/19/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
5/20/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
7/19/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings
8/18/2022

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
7/13/2022Cantor FitzgeraldReiterated RatingNeutralLow
6/7/2022HC WainwrightDowngradeBuy ➝ NeutralLow
5/6/2022Cantor FitzgeraldDowngradeOverweight ➝ NeutralHigh
3/11/2022HC WainwrightLower TargetBuy$150.00 ➝ $125.00Low
11/12/2021HC WainwrightLower TargetBuy$200.00 ➝ $150.00High
8/5/2021CowenLower TargetOutperform$450.00 ➝ $250.00Low
1/28/2021HC WainwrightLower TargetBuy$250.00 ➝ $200.00High
11/10/2020HC WainwrightReiterated RatingBuyLow
11/10/2020Cantor FitzgeraldReiterated RatingOverweightLow
9/29/2020HC WainwrightReiterated RatingBuyHigh
8/7/2020Jefferies Financial GroupDowngradeHold ➝ Underperform$62.50 ➝ $60.00Low
7/22/2020Noble FinancialReiterated RatingBuy$500.00High
5/19/2020JPMorgan Chase & Co.DowngradeOverweight ➝ NeutralHigh
5/7/2020HC WainwrightReiterated RatingBuy$300.00 ➝ $250.00Low
4/16/2020Stifel NicolausBoost TargetBuy$700.00 ➝ $750.00Medium
3/29/2020HC WainwrightReiterated RatingBuy$300.00Low
2/21/2020HC WainwrightLower TargetBuy$350.00 ➝ $300.00High
2/5/2020Noble FinancialReiterated RatingBuy$650.00High
12/23/2019HC WainwrightReiterated RatingBuy$350.00High
12/2/2019GuggenheimInitiated CoverageBuy$250.00High
10/29/2019HC WainwrightReiterated RatingBuy$350.00Low
10/28/2019Stifel NicolausLower TargetBuy$1,000.00 ➝ $850.00Low
10/17/2019HC WainwrightInitiated CoverageBuy$350.00Medium
9/27/2019Stifel NicolausSet TargetBuy$1,000.00High
9/27/2019Noble FinancialReiterated RatingBuy$650.00High
8/22/2019OppenheimerSet TargetBuy$450.00High
8/12/2019Noble FinancialReiterated RatingBuy$650.00High
8/7/2019Cantor FitzgeraldReiterated RatingOverweight$650.00 ➝ $650.00High
7/15/2019Jefferies Financial GroupLower TargetHold$200.00 ➝ $150.00Low
6/12/2019Cantor FitzgeraldLower TargetOverweight$1,350.00 ➝ $650.00High
6/11/2019OppenheimerLower TargetOutperform$650.00 ➝ $500.00High
6/11/2019CowenLower TargetOutperform$800.00 ➝ $450.00High
6/11/2019JPMorgan Chase & Co.Lower TargetBuy$400.00 ➝ $300.00High
5/7/2019Jefferies Financial GroupLower TargetHold$250.00 ➝ $200.00High
4/30/2019Noble FinancialReiterated RatingOutperform ➝ Outperform$650.00High
4/18/2019Cantor FitzgeraldReiterated RatingOverweight ➝ PositiveMedium
3/19/2019OppenheimerReiterated RatingBuyLow
2/11/2019OppenheimerSet TargetBuy$700.00Low
1/21/2019Cantor FitzgeraldReiterated RatingBuy$1,350.00Low
11/23/2018Cantor FitzgeraldReiterated RatingOverweightHigh
11/7/2018OppenheimerSet TargetBuy$700.00N/A
11/7/2018Cantor FitzgeraldSet TargetBuy$1,350.00N/A
10/29/2018Cantor FitzgeraldSet TargetBuy$1,350.00High
10/14/2018Cantor FitzgeraldSet TargetBuy$1,350.00Low
10/2/2018OppenheimerSet TargetBuy$700.00High
9/27/2018Cantor FitzgeraldSet TargetBuy$1,350.00High
9/26/2018OppenheimerSet TargetBuy$700.00N/A
9/5/2018OppenheimerSet TargetBuy$700.00Medium
8/15/2018JPMorgan Chase & Co.Set TargetBuy$550.00Low
8/14/2018Cantor FitzgeraldBoost TargetOverweight ➝ Overweight$1,300.00 ➝ $1,350.00High
8/13/2018OppenheimerSet TargetBuy$700.00High
8/10/2018Cantor FitzgeraldSet TargetBuy$1,300.00Low
8/5/2018OppenheimerSet TargetBuy$600.00Low
7/30/2018OppenheimerSet TargetBuy$600.00High
7/30/2018Cantor FitzgeraldSet TargetBuy$1,300.00High
6/15/2018JPMorgan Chase & Co.Initiated CoverageOverweight$550.00High
6/5/2018OppenheimerSet TargetBuy$600.00High
5/30/2018OppenheimerSet TargetBuy$600.00Medium
5/3/2018OppenheimerSet TargetBuy$500.00High
3/21/2018OppenheimerReiterated RatingBuyMedium
3/9/2018Noble FinancialReiterated RatingBuyMedium
3/8/2018OppenheimerSet TargetBuy$500.00High
2/22/2018Noble FinancialReiterated RatingBuyHigh
2/21/2018OppenheimerSet TargetBuy$500.00High
1/28/2018OppenheimerReiterated RatingBuy$500.00Low
1/7/2018Cantor FitzgeraldReiterated RatingBuy$1,400.00Low
12/29/2017Noble FinancialReiterated RatingBuyN/A
12/28/2017Cantor FitzgeraldReiterated RatingBuy$1,400.00Medium
12/20/2017Noble FinancialReiterated RatingBuyLow
12/20/2017OppenheimerSet TargetBuy$500.00Low
12/20/2017Deutsche Bank AktiengesellschaftSet TargetBuy$450.00High
11/30/2017Noble FinancialReiterated RatingBuyMedium
11/29/2017Cantor FitzgeraldReiterated RatingBuy$1,550.00Low
11/6/2017CowenReiterated RatingOutperform$650.00 ➝ $800.00N/A
10/16/2017OppenheimerSet TargetBuy$500.00N/A
9/26/2017Jefferies Financial GroupReiterated RatingBuy$750.00Medium
9/13/2017Deutsche Bank AktiengesellschaftReiterated RatingBuy$500.00Medium
9/8/2017Jefferies Financial GroupReiterated RatingBuy$750.00Low
9/8/2017Morgan StanleyInitiated CoverageEqual Weight$300.00N/A
9/4/2017Cantor FitzgeraldReiterated RatingBuy$1,650.00Medium
8/31/2017OppenheimerReiterated RatingOutperform$500.00High
8/22/2017Deutsche Bank AktiengesellschaftSet TargetBuy$500.00Low
8/21/2017Stifel NicolausReiterated RatingBuy$1,000.00Low
(Data available from 8/18/2017 forward)

News Sentiment Rating

0.37 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 4 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/20/2022
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/19/2022
  • 3 very positive mentions
  • 21 positive mentions
  • 6 negative mentions
  • 3 very negative mentions
3/21/2022
  • 1 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/20/2022
  • 1 very positive mentions
  • 8 positive mentions
  • 6 negative mentions
  • 0 very negative mentions
5/20/2022
  • 10 very positive mentions
  • 18 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
6/19/2022
  • 5 very positive mentions
  • 8 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
7/19/2022
  • 3 very positive mentions
  • 22 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/18/2022

Current Sentiment

  • 3 very positive mentions
  • 22 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
TherapeuticsMD logo
TherapeuticsMD, Inc. operates as a women's healthcare company in the United States. The company offers IMVEXXY for the treatment of moderate-to-severe dyspareunia; BIJUVA, a bio-identical hormone therapy combination of 17ß-estradiol and progesterone for the treatment of moderate-to-severe vasomotor symptoms; and ANNOVERA, a ring-shaped contraceptive vaginal system. Its preclinical projects include the development of TX-005HR, a progesterone-alone transdermal cream; TX-006HR, an estradiol and progesterone transdermal cream; TX-007HR and TX-008HR, which are transdermal patch product candidates; and TX-009HR, an oral progesterone and estradiol formulation. It also manufactures and distributes branded and generic prescription prenatal vitamins under the vitaTrue, vitaPearl, vitaMedMD, and BocaGreenMD Prena1 brands. The company sells its prescription pharmaceutical products and prenatal vitamin products to wholesale distributors and retail pharmacy distributors. TherapeuticsMD, Inc. was founded in 2008 and is headquartered in Boca Raton, Florida.
Read More

Today's Range

Now: $10.10
Low: $10.05
High: $10.20

50 Day Range

MA: $7.34
Low: $4.72
High: $10.20

52 Week Range

Now: $10.10
Low: $1.99
High: $43.36

Volume

1,547 shs

Average Volume

760,940 shs

Market Capitalization

$95.14 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.67

Frequently Asked Questions

What sell-side analysts currently cover shares of TherapeuticsMD?

The following Wall Street sell-side analysts have issued research reports on TherapeuticsMD in the last year: Cantor Fitzgerald, HC Wainwright, and StockNews.com.
View the latest analyst ratings for TXMD.

What is the current price target for TherapeuticsMD?

1 Wall Street analysts have set twelve-month price targets for TherapeuticsMD in the last year. Their average twelve-month price target is $125.00, suggesting a possible upside of 1,137.6%. HC Wainwright has the highest price target set, predicting TXMD will reach $125.00 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $125.00 for TherapeuticsMD in the next year.
View the latest price targets for TXMD.

What is the current consensus analyst rating for TherapeuticsMD?

TherapeuticsMD currently has 2 hold ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in TXMD, but not buy more shares or sell existing shares.
View the latest ratings for TXMD.

What other companies compete with TherapeuticsMD?

How do I contact TherapeuticsMD's investor relations team?

TherapeuticsMD's physical mailing address is 951 Yamato Road Suite 220, BOCA RATON FL, 33431. The company's listed phone number is (561) 961-1900 and its investor relations email address is [email protected] The official website for TherapeuticsMD is www.therapeuticsmd.com. Learn More about contacing TherapeuticsMD investor relations.